LifeStance (LFST) Files Form 144 for 35,938 Shares via Morgan Stanley

Rhea-AI Filing Summary

LifeStance Health Group, Inc. (LFST) Form 144 notifies the market of a proposed sale of 35,938 shares of common stock through Morgan Stanley & Co. LLC, with an aggregate market value of $194,424.58. The filing states the securities will be sold approximately on 08/18/2025 on NASDAQ and shows 388,936,394 shares outstanding. The shares were originally acquired 06/10/2021 in a pre-IPO transaction (206,219 shares acquired) from LifeStance Health Group Inc. No sales by the seller are reported in the past three months.

Insights

Financial Analyst

TL;DR: Routine insider sale notice; modest size relative to outstanding shares, likely immaterial to market valuation.

The Form 144 discloses a planned sale of 35,938 shares valued at $194,424.58, executed through Morgan Stanley on NASDAQ. Compared with the reported 388.9 million shares outstanding, the volume represents a de minimis portion of the float. The filing also documents the acquisition source and date (pre-IPO on 06/10/2021) and confirms no sales in the past three months. From a financial-impact perspective, the disclosed sale is small and unlikely to move market pricing or materially change ownership percentages.

Corporate Governance Expert

TL;DR: Filing meets basic disclosure requirements but omits some identifying details that reduce transparency.

The notice includes required transaction-level details: broker, share count, market value, acquisition date and nature, and intended sale date. However, key filer identifiers and a dated signature block are absent from the provided content, which complicates verification of the seller's identity and the attestation timing. While the document asserts the seller has no undisclosed material information, the missing administrative fields limit independent confirmation of compliance with all procedural requirements.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley & Co. LLC 1585 Broadway New York NY 10036	35938	194424.58	388936394	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/10/2021	Pre-IPO Transactions	LifeStance Health Group Inc.			206219	06/10/2021	Equity interests in the Issuer were purchased pre-IPO.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares is LFST planning to sell according to this Form 144?

The filing states a proposed sale of 35,938 shares of LFST common stock through Morgan Stanley with an aggregate market value of $194,424.58.

When is the LFST sale expected to occur?

The filing lists an approximate sale date of 08/18/2025 on NASDAQ.

How were the securities being sold originally acquired?

The securities were acquired on 06/10/2021 in a pre-IPO transaction from LifeStance Health Group Inc., totaling 206,219 shares acquired at that time.

Has the seller reported other LFST sales in the past three months?

No; the Form 144 indicates Nothing to Report for securities sold in the past three months by the person for whose account the securities are to be sold.

Does the filing include the filer’s contact and identification details?

In the provided content excerpt, explicit filer identifiers (CIK/CCC) and submission contact details are not shown.